<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40820495</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-6535</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>17</Day></PubDate></JournalIssue><Title>Clinical pharmacology and therapeutics</Title><ISOAbbreviation>Clin Pharmacol Ther</ISOAbbreviation></Journal><ArticleTitle>Emulating Six Cardiovascular Outcome Trials of Antidiabetic Drugs in Individuals with Type 2 Diabetes: Analyses Based on Real-World Databases from Korea and Taiwan.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/cpt.70027</ELocationID><Abstract><AbstractText>With the increasing volume of clinical evidence derived from large-scale Asian real-world data (RWD) and the growing interest in its use in regulatory decision-making, it is important to conduct benchmarking exercises that evaluate whether studies using Asian RWD can generate similar conclusions as randomized controlled trials (RCTs). We aimed to assess whether observational studies based on Korea and Taiwan RWD can yield comparable results with trials by emulating six cardiovascular outcome trials (CVOTs) of antidiabetic drugs in individuals with type 2 diabetes (T2D). We emulated six CVOTs using nationwide claims of Korea and Taiwan. An active comparator, new-user design was applied, and observational analogues to the eligibility criteria and outcomes of the corresponding RCT were implemented. Propensity score matching was utilized to balance the treatment groups. Hazard ratios and 95% confidence intervals (CI) were estimated and compared with corresponding RCT estimates. We used three pre-specified binary agreement metrics that have been used in prior benchmarking studies to define concordance in results. Results from each of the six emulations were concordant with the corresponding CVOT on &#x2265;&#x2009;1 binary agreement metric. Five out of six emulations indicated superiority when the corresponding CVOT only demonstrated non-inferiority. Results from emulations were more concordant with Asian-specific results from RCT, with four emulations meeting all agreement metrics. In this binational study using two Asian healthcare claims data, emulations yielded comparable clinical conclusions with the corresponding RCT, increasing the confidence in the validity of RWE studies in patients with T2D using these databases.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Clinical Pharmacology &amp; Therapeutics published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>Hwa Yeon</ForeName><Initials>HY</Initials><Identifier Source="ORCID">0000-0001-5297-8826</Identifier><AffiliationInfo><Affiliation>School of Pharmacy, Sungkyunkwan University, Suwon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Au</LastName><ForeName>Philip C M</ForeName><Initials>PCM</Initials><Identifier Source="ORCID">0000-0002-0736-4726</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology and Pharmacy, Centre for Safe Medication Practice and Research, University of Hong Kong, Hong Kong City, Hong Kong.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Michael Chun-Yuan</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0002-8640-3593</Identifier><AffiliationInfo><Affiliation>School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Population Health Data Center, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheung</LastName><ForeName>Ching-Lung</ForeName><Initials>CL</Initials><Identifier Source="ORCID">0000-0002-6233-9144</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology and Pharmacy, Centre for Safe Medication Practice and Research, University of Hong Kong, Hong Kong City, Hong Kong.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Ahhyung</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0101-7328</Identifier><AffiliationInfo><Affiliation>School of Pharmacy, Sungkyunkwan University, Suwon, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsieh</LastName><ForeName>Miyuki Hsing-Chun</ForeName><Initials>MH</Initials><Identifier Source="ORCID">0000-0002-7995-7408</Identifier><AffiliationInfo><Affiliation>School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Population Health Data Center, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeong</LastName><ForeName>Han Eol</ForeName><Initials>HE</Initials><Identifier Source="ORCID">0000-0001-6678-0941</Identifier><AffiliationInfo><Affiliation>School of Pharmacy, Sungkyunkwan University, Suwon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Edward Chia-Cheng</ForeName><Initials>EC</Initials><Identifier Source="ORCID">0000-0002-5852-7652</Identifier><AffiliationInfo><Affiliation>School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Population Health Data Center, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Brian Meng-Hsun</ForeName><Initials>BM</Initials><Identifier Source="ORCID">0009-0007-7445-8806</Identifier><AffiliationInfo><Affiliation>School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Population Health Data Center, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Man</LastName><ForeName>Kenneth K C</ForeName><Initials>KKC</Initials><Identifier Source="ORCID">0000-0001-8645-1942</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology and Pharmacy, Centre for Safe Medication Practice and Research, University of Hong Kong, Hong Kong City, Hong Kong.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Department of Practice and Policy, School of Pharmacy, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rassen</LastName><ForeName>Jeremy A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0003-4369-7381</Identifier><AffiliationInfo><Affiliation>Aetion, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Daniel Hsiang-Te</ForeName><Initials>DH</Initials><Identifier Source="ORCID">0000-0003-2841-0338</Identifier><AffiliationInfo><Affiliation>School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Population Health Data Center, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Shirley V</ForeName><Initials>SV</Initials><Identifier Source="ORCID">0000-0001-7761-7090</Identifier><AffiliationInfo><Affiliation>Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Ian C K</ForeName><Initials>ICK</Initials><Identifier Source="ORCID">0000-0001-8242-0014</Identifier><AffiliationInfo><Affiliation>Department of Pharmacology and Pharmacy, Centre for Safe Medication Practice and Research, University of Hong Kong, Hong Kong City, Hong Kong.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Department of Practice and Policy, School of Pharmacy, University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Aston Pharmacy School, Aston University, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shin</LastName><ForeName>Ju-Young</ForeName><Initials>JY</Initials><Identifier Source="ORCID">0000-0003-1010-7525</Identifier><AffiliationInfo><Affiliation>School of Pharmacy, Sungkyunkwan University, Suwon, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Sohee</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-7829-4131</Identifier><AffiliationInfo><Affiliation>School of Pharmacy, Sungkyunkwan University, Suwon, South Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Aston Pharmacy School, Aston University, Birmingham, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Pharmacol Ther</MedlineTA><NlmUniqueID>0372741</NlmUniqueID><ISSNLinking>0009-9236</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>18</Day><Hour>3</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40820495</ArticleId><ArticleId IdType="doi">10.1002/cpt.70027</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sherman, R.E. et al. Real&#x2010;world evidence &#x2013; what is it and what can it tell us? N. Engl. J. Med. 375, 2293&#x2013;2297 (2016).</Citation></Reference><Reference><Citation>Eichler, H.G. et al. Randomized controlled trials versus real world evidence: neither magic nor myth. Clin. Pharmacol. Ther. 109, 1212&#x2013;1218 (2021).</Citation></Reference><Reference><Citation>European Medicines Agency. Real&#x2010;world evidence framework to support EU regulatory decision&#x2010;making: 2nd report on the experience gained with regulator&#x2010;led studies from February 2023 to February 2024. EMA, 180299 (2024).</Citation></Reference><Reference><Citation>US Food and Drug Administration. Framework for FDA's real&#x2010;world evidence program &lt;https://www.fda.gov/media/120060/download&gt;. (2018) Accessed August 1, 2024.</Citation></Reference><Reference><Citation>Wang, S.V. &amp; Schneeweiss, S. Assessing and interpreting real&#x2010;world evidence studies: introductory points for new reviewers. Clin. Pharmacol. Ther. 111, 145&#x2013;149 (2022).</Citation></Reference><Reference><Citation>Franklin, J.M., Patorno, E., Desai, R.J. et al. Emulating randomized clinical trials with nonrandomized real&#x2010;world evidence studies: first results from the RCT DUPLICATE initiative. Circulation 143, 1002&#x2013;1013 (2021).</Citation></Reference><Reference><Citation>Khosrow&#x2010;Khavar, F., Kim, S.C., Lee, H., Lee, S.B. &amp; Desai, R.J. Tofacitinib and risk of cardiovascular outcomes: results from the safety of TofAcitinib in routine care patients with rheumatoid arthritis (STAR&#x2010;RA) study. Ann. Rheum. Dis. 81, 798&#x2013;804 (2022).</Citation></Reference><Reference><Citation>Wing, K. et al. Real world effects of COPD medications: a cohort study with validation against results from randomised controlled trials. Eur. Respir. J. 57, 2001586 (2021).</Citation></Reference><Reference><Citation>Franklin, J.M. et al. When can nonrandomized studies support valid inference regarding effectiveness or safety of new medical treatments? Clin. Pharmacol. Ther. 111, 108&#x2013;115 (2022).</Citation></Reference><Reference><Citation>Franklin, J.M., Liaw, K.L., Iyasu, S., Critchlow, C.W. &amp; Dreyer, N.A. Real&#x2010;world evidence to support regulatory decision making: new or expanded medical product indications. Pharmacoepidemiol. Drug Saf. 30, 685&#x2013;693 (2021).</Citation></Reference><Reference><Citation>Dreyer, N.A. Advancing a framework for regulatory use of real&#x2010;world evidence: when real is reliable. Ther. Innov. Regul. Sci. 52, 362&#x2013;368 (2018).</Citation></Reference><Reference><Citation>Simon, G.E. et al. When can we trust real&#x2010;world data to evaluate new medical treatments? Clin. Pharmacol. Ther. 111, 24&#x2013;29 (2022).</Citation></Reference><Reference><Citation>Wang, S.V. et al. Emulation of randomized clinical trials with nonrandomized database analyses: results of 32 clinical trials. JAMA 329, 1376&#x2013;1385 (2023).</Citation></Reference><Reference><Citation>Deng, Y. et al. Emulating the GRADE trial using real world data: retrospective comparative effectiveness study. BMJ 379, e070717 (2022).</Citation></Reference><Reference><Citation>Kirchgesner, J., Desai, R.J., Beaugerie, L., Kim, S.C. &amp; Schneeweiss, S. Calibrating real&#x2010;world evidence studies against randomized trials: treatment effectiveness of infliximab in Crohn's disease. Clin. Pharmacol. Ther. 111, 179&#x2013;186 (2022).</Citation></Reference><Reference><Citation>Hsieh, C.Y. et al. Taiwan's National Health Insurance Research Database: past and future. Clin. Epidemiol. 11, 349&#x2013;358 (2019).</Citation></Reference><Reference><Citation>Tsai, D.H. et al. Cross&#x2010;regional data initiative for the assessment and development of treatment for neurological and mental disorders. Clin. Epidemiol. 15, 1241&#x2013;1252 (2023).</Citation></Reference><Reference><Citation>Rosenstock, J. et al. Effect of Linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA 322, 1155&#x2013;1166 (2019).</Citation></Reference><Reference><Citation>Rosenstock, J. et al. Effect of Linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA 321, 69&#x2013;79 (2019).</Citation></Reference><Reference><Citation>Green, J.B. et al. Effect of Sitagliptin on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 373, 232&#x2013;242 (2015).</Citation></Reference><Reference><Citation>Scirica, B.M. et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 369, 1317&#x2013;1326 (2013).</Citation></Reference><Reference><Citation>Wiviott, S.D. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 380, 347&#x2013;357 (2019).</Citation></Reference><Reference><Citation>Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117&#x2013;2128 (2015).</Citation></Reference><Reference><Citation>Neal, B. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 644&#x2013;657 (2017).</Citation></Reference><Reference><Citation>Marso, S.P. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 311&#x2013;322 (2016).</Citation></Reference><Reference><Citation>Lund, J.L., Richardson, D.B. &amp; St&#xfc;rmer, T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr. Epidemiol. Rep. 2, 221&#x2013;228 (2015).</Citation></Reference><Reference><Citation>Suissa, S. &amp; Azoulay, L. Metformin and the risk of cancer: time&#x2010;related biases in observational studies. Diabetes Care 35, 2665&#x2013;2673 (2012).</Citation></Reference><Reference><Citation>9. Pharmacologic approaches to glycemic treatment: standards of Care in Diabetes&#x2010;2024. Diabetes Care 47(Suppl 1), S158&#x2013;S178 (2024).</Citation></Reference><Reference><Citation>Higgins, J.P., Thompson, S.G., Deeks, J.J. &amp; Altman, D.G. Measuring inconsistency in meta&#x2010;analyses. BMJ 327, 557&#x2013;560 (2003).</Citation></Reference><Reference><Citation>Franklin, J.M. et al. Nonrandomized real&#x2010;world evidence to support regulatory decision making: process for a randomized trial replication project. Clin. Pharmacol. Ther. 107, 817&#x2013;826 (2020).</Citation></Reference><Reference><Citation>Desai, R.J. et al. Process guide for inferential studies using healthcare data from routine clinical practice to evaluate causal effects of drugs (PRINCIPLED): considerations from the FDA sentinel innovation center. BMJ 384, e076460 (2024).</Citation></Reference><Reference><Citation>Eriksson, J.W., Bodegard, J., Nathanson, D., Thuresson, M., Nystr&#xf6;m, T. &amp; Norhammar, A. Sulphonylurea compared to DPP&#x2010;4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all&#x2010;cause mortality. Diabetes Res. Clin. Pract. 117, 39&#x2013;47 (2016).</Citation></Reference><Reference><Citation>Liu, J. et al. Sodium&#x2010;glucose co&#x2010;transporter&#x2010;2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: a systematic review and meta&#x2010;analysis of randomized controlled trials. Diabetes Obes. Metab. 22, 1619&#x2013;1627 (2020).</Citation></Reference><Reference><Citation>Kosiborod, M. et al. Lower risk of heart failure and death in patients initiated on sodium&#x2010;glucose Cotransporter&#x2010;2 inhibitors versus other glucose&#x2010;lowering drugs: the CVD&#x2010;REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium&#x2010;glucose Cotransporter&#x2010;2 inhibitors). Circulation 136, 249&#x2013;259 (2017).</Citation></Reference><Reference><Citation>Shin, H., Schneeweiss, S., Glynn, R.J. &amp; Patorno, E. Trends in first&#x2010;line glucose&#x2010;lowering drug use in adults with type 2 diabetes in light of emerging evidence for SGLT&#x2010;2i and GLP&#x2010;1RA. Diabetes Care 44, 1774&#x2013;1782 (2021).</Citation></Reference><Reference><Citation>Lim, L.L. et al. Real&#x2010;world usage of sulphonylureas in Asian patients with type 2 diabetes using the joint Asia diabetes evaluation (JADE) register. Diabetes Obes. Metab. 25, 208&#x2013;221 (2023).</Citation></Reference><Reference><Citation>M&#xf8;ller, J.B. et al. Body composition is the main determinant for the difference in type 2 diabetes pathophysiology between Japanese and Caucasians. Diabetes Care 37, 796&#x2013;804 (2014).</Citation></Reference><Reference><Citation>Lee, J.W., Brancati, F.L. &amp; Yeh, H.C. Trends in the prevalence of type 2 diabetes in Asians versus whites: results from the United States National Health Interview Survey, 1997&#x2010;2008. Diabetes Care 34, 353&#x2013;357 (2011).</Citation></Reference><Reference><Citation>Ueshima, H. et al. Cardiovascular disease and risk factors in Asia: a selected review. CirculationCirculation 118, 2702&#x2013;2709 (2008).</Citation></Reference><Reference><Citation>Schwartz, A.L., Alsan, M., Morris, A.A. &amp; Halpern, S.D. Why diverse clinical trial participation matters. N. Engl. J. Med. 388, 1252&#x2013;1254 (2023).</Citation></Reference><Reference><Citation>US Food and Drug Administration. Diversity action plans to improve enrollment of participants from underrepresented populations in clinical studies guidance for industry &lt;https://www.fda.gov/media/179593/download&gt;. (2024) Accessed August 1, 2024.</Citation></Reference><Reference><Citation>Gan, S. et al. Efficacy of modern diabetes treatments DPP&#x2010;4i, SGLT&#x2010;2i, and GLP&#x2010;1RA in white and Asian patients with diabetes: a systematic review and meta&#x2010;analysis of randomized controlled trials. Diabetes Care 43, 1948&#x2013;1957 (2020).</Citation></Reference><Reference><Citation>Singh, A.K. &amp; Singh, R. Cardiovascular outcomes with SGLT&#x2010;2 inhibitors and GLP&#x2010;1 receptor agonist in Asians with type 2 diabetes: a systematic review and meta&#x2010;analysis of cardiovascular outcome trials. Diabetes Metab. Syndr. 14, 715&#x2013;722 (2020).</Citation></Reference><Reference><Citation>Cheol Seong, S. et al. Data resource profile: the National Health Information Database of the National Health Insurance Service in South Korea. Int. J. Epidemiol. 46, 799&#x2013;800 (2017).</Citation></Reference><Reference><Citation>Lin, L.Y., Warren&#x2010;Gash, C., Smeeth, L. &amp; Chen, P.C. Data resource profile: the National Health Insurance Research Database (NHIRD). Epidemiol. Health 40, e2018062 (2018).</Citation></Reference><Reference><Citation>Schneeweiss, S. &amp; Patorno, E. Conducting real&#x2010;world evidence studies on the clinical outcomes of diabetes treatments. Endocr. Rev. 42, 658&#x2013;690 (2021).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>